Apamin administration impact on miR-219 and miR-155-3p expression in cuprizone induced multiple sclerosis model
- PDF / 1,002,645 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 85 Downloads / 153 Views
ORIGINAL ARTICLE
Apamin administration impact on miR‑219 and miR‑155‑3p expression in cuprizone induced multiple sclerosis model Samira Gholami1 · Mina Mirian2 · Seyed Mehdi Eftekhari3 · Mehdi Aliomrani4 Received: 1 August 2020 / Accepted: 29 October 2020 / Published online: 10 November 2020 © Springer Nature B.V. 2020
Abstract Multiple sclerosis (MS) is a chronic debilitating disease that attacks the central nervous system. This study aims to investigate miR-219 and miR-155-3p expression levels involved in the myelination process following the administration of apamin peptide in the model of multiple sclerosis disease. Forty-four 8 week C57BL/6 male mice (22 ± 5 g) randomly divided into six groups. Apamin (100 µg/kg/BW) was administered intraperitoneally as a co-treatment during phase I (demyelination) or post-treatment phase II (remyelination) twice a week in cuprizone induced MS model. At the end of study myelin content and microRNA expression levels were measured with LFB staining and quantitative Real-Time PCR method, respectively. It was observed that the intended microRNAs were dysregulated during the different phases of disease induction. After 6 weeks of cuprizone exposure, miR-219 downregulated in phase I in comparison with the negative control. On the other hand, the apamin co-treatment significantly inhibit the miR-155-3p upregulation during the phase I as compared with the cuprizone group (p < 0.0001). Apamin has more impact on the miR155-3p reduction in phase I than miR-219 elevation in phase II. It could be considered as a therapeutic option for decreasing plaque formation during the exacerbation phase of the MS disease. Apamin has more impact on the miR155-3p reduction in phase I than miR-219 elevation in phase II. It could be considered as a therapeutic option for decreasing plaque formation during the exacerbation phase of the MS disease. Keywords miR-155-3p · miR-219 · Apamin · Multiple sclerosis · Myelination · Cuprizone
Introduction Multiple sclerosis (MS) is one of the most prevalent neurological diseases in young adults characterized by numerous demyelinated plaques scattered in the central nervous system (CNS) [1]. It is reported that around 2.1 million people * Mehdi Aliomrani [email protected] 1
School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran
2
Department of Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran
3
Clinical Pathologist, Azarmehr Pathology Laboratory, Isfahan, Iran
4
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Isfahan Pharmaceutical Science Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Room 117, Isfahan, Islamic Republic of Iran
are challenged with MS Worldwide and its incidence rate increased regardless of the living region [2]. Recent studies reported that clinical symptoms in MS may be resolved by inducing the re
Data Loading...
